Small US biotech DNDN, is about to have its trial results published in the Journal of Clinical Oncology in the next few days. They have a prostate(AIPC) cancer vaccine that extends survival over the best current treatment, which is the chemo Taxotere, while eliminating the chemo side effects. Building a plant in NJ to service the US market. Trials are complete. Yet to be approved by the FDA.
